“Our Speculative Trading Indicator has increased sharply during the last few months,” Goldman Sachs wrote, noting the current level is now the highest on record apart from 1998–2001 and 2020–2021. The ...

Investing.com -- Moody’s Ratings has upgraded Intrum AB’s corporate family rating to Caa2 from Ca following the completion of the company’s court-supervised debt restructuring process.

Investing.com -- Moody’s Ratings has affirmed Ayvens’ long-term issuer and senior unsecured debt ratings at A1 and changed the outlook to stable from negative, the rating agency announced Friday. The ...

Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has formed a strategic partnership with Tether to accelerate cryptocurrency adoption across Brazil through institutional ...

S&P Global Ratings has downgraded Singapore Post Ltd. to ’BBB-’ from ’BBB’ with a stable outlook following the company’s significant operational scale-down. The rating action comes after SingPost ...

Investing.com -- Jefferies upgraded Union Pacific (NYSE: UNP) and downgraded Norfolk Southern (NYSE: NSC) saying the former ...

Investing.com -- Palantir Technologies is a high-risk but potentially transformative investment, according to Piper Sandler, ...

Investing.com -- United States Cellular Corporation (NYSE: USM) stock jumped 7% after announcing plans for a special cash ...

The offering, expected to close on July 28, 2025, will allow Apollo to reduce its stake in the company. Underwriters will have a 30-day option to purchase an additional 10.65 million shares from the ...

Investing.com -- Oppenheimer upgraded Carvana (NYSE: CVNA) to Outperform from Perform saying investors continue to ...

Investing.com -- Elanco Animal Health (NYSE: ELAN) stock rose 2.6% following the European Commission’s approval of Zenrelia, a once-daily oral treatment for canine allergic dermatitis.

The clinical-stage biopharmaceutical company revealed that NC605 demonstrated improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment in a well-established ...